N/A
Completed N=197
Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
Post Herpetic Neuralgia
Source: ClinicalTrials.gov NCT01426230 ↗
Enrolled (actual)
197
Serious AEs
2.5%
Results posted
Mar 2013
Primary outcomePrimary: Change From Baseline to End of Study in LOCF VAS — -20.4; -21.3 scores on a scale
Summary
Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline to End of Study in LOCF VAS |
-20.4; -21.3 | — |
Eligibility Criteria
Inclusion Criteria
- Men or Women 18 years or older who are suffering from PHN
Exclusion Criteria
- Patient is Pregnant or a nursing mother
- Patient has hypersensitivity to gabapentin
- Patient has an estimated creatinine clearance of <30 mL/min or is in hemodialysis
Data sourced from ClinicalTrials.gov (NCT01426230). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.